What Mimesis does

Mimesis S.r.l. (mimesis.srl) is an Italian computational medicine company founded in 2020 as a spin-off of the University of Catania and headquartered at the Department of Drug and Health Sciences, University of Catania (Viale A. Doria, 6, 95125 Catania). The company operates the Universal Immune System Simulator (UISS), a proprietary agent-based platform with multi-layer (Physiology, Disease, Treatment) simulation capabilities that replicates human immune system behavior to predict disease progression and therapeutic outcomes. Its commercial offering spans (a) the core UISS engine, (b) nine named ready-to-use disease applications covering mammary carcinoma, thyroid carcinoma, melanoma, multiple sclerosis, COVID-19, influenza, skin sensitization (Sense), immunotoxicity (TOX), and drug-resistant tuberculosis (TB-DR), and (c) three tiered service packages (Mimesis One / Evo / Custom) with a Therapy Combination Simulation add-on. Target customers include pharmaceutical and nutraceutical companies, academic researchers, clinicians, and public/private health agencies.

The business model mixes subscription software licensing (annual Mimesis One/Evo/Custom tiers) and one-time licensing of ready-to-use disease modules with professional services for fully bespoke disease models and personalized in silico trials; pricing is quote-based and not publicly disclosed. Go-to-market is direct B2B via website contact forms with Calendly scheduling, conference-driven engagement (World Vaccine Congress, VPH2024, Avicenna Days, CMISF 2023, SMAU, Borsa della Ricerca), and academic partnership channels anchored at the University of Catania. Mimesis is privately held with 1-10 employees, no disclosed external institutional investors, and a single disclosed capital raise of approximately $1,400,000 in March 2022. The technology has received world-first preliminary regulatory acceptance (Letter of Support) from the European Medicines Agency for the UISS-TB-DR platform within the In Silico World Consortium, and the company holds leadership roles in the Avicenna Alliance and the VPH/ICSC ecosystems via its co-founders Professor Francesco Pappalardo and Dr. Giulia Russo.

Name

Mimesis

Legal name

Mimesis S.r.l.

Website

https://mimesis.srl

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Mimesis S.r.l., a 2020 spin-off of the University of Catania, operates the UISS agent-based Universal Immune System Simulator platform to deliver in silico drug development, vaccine simulation, and personalized treatment prediction for pharmaceutical and nutraceutical companies, academic researchers, clinicians, and public health agencies.

Ownership category

akta.pro rank

Product category

In Silico Drug Development Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Custom Computer Programming Services (541511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Computer Programming Services (7371)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industries

Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• In silico drug development
• Computational immunology platform
• Agent-based simulation software
• Vaccine development modeling
• Immune system simulator

Headquarters

HQ city

Catania

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. UISS Software Simulation Services: Provides in silico simulation services to pharmaceutical and biotech companies for drug development, vaccine design, and therapeutic optimization. Revenue generated through custom modeling projects and ready-to-use product licenses.
2. Product Packages (Mimesis One, Evo, Custom): Tiered product offerings: Mimesis One (single-drug modeling), Mimesis Evo (multi-drug and disease modeling), Mimesis Custom (fully bespoke disease models). Additional therapy combination simulation add-ons available.
3. Professional Services: End-to-end development of disease models and drug simulations for clients seeking novel disease models and personalized in silico trials.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Mimesis develops and licenses the Universal Immune System Simulator (UISS), a proprietary agent-based computational platform that simulates human immune system responses across Physiology, Disease, and Treatment layers. The company supplies disease-specific Ready-to-Use UISS models for mammary carcinoma, thyroid carcinoma, melanoma, multiple sclerosis, COVID-19, influenza, skin sensitization, immunotoxicity, and drug-resistant tuberculosis, and offers tiered in silico trial services (Mimesis One, Evo, Custom) to pharmaceutical, biotech, nutraceutical, academic, and clinical customers worldwide.

Product overview

Mimesis offers a unified computational platform architecture centered on the Universal Immune System Simulator (UISS), an agent-based model with three simulation layers (Physiology, Disease, Treatment). The platform is complemented by Ready-to-Use Products targeting specific therapeutic areas (mammary carcinoma, thyroid carcinoma, melanoma, multiple sclerosis, COVID-19, flu, skin sensitization, immunotoxicity). Service packages (Mimesis One, Mimesis Evo, Mimesis Custom) provide tiered access from single-drug modeling to fully bespoke disease simulations, with Therapy Combination Simulation as an add-on for multi-drug strategies.

Differentiator

Problem solved

Functional benefit

Products and services

• Universal Immune System Simulator (UISS) Proprietary agent-based computational model that replicates the complexity of the human immune system using multi-layer simulation covering Physiology, Disease, and Treatment, enabling in silico trials to predict disease progression and treatment effects for drug and vaccine development.
• UISS-Mammary Carcinoma (UISS-MC) Agent-based model simulating tumor-preventive cell vaccines against mammary carcinoma in HER-2/neu transgenic mice, optimized via genetic algorithms to design cancer-preventive vaccination protocols.
• UISS-Thyroid Carcinoma Computational platform analyzing therapeutic resistance in thyroid cancer, particularly BRAF V600E mutation cases, to identify potential targets such as MAP3K8 that overcome drug resistance.
• UISS-Melanoma In silico platform replicating complex melanoma immunotherapy dynamics, including tumor-specific cytotoxic T lymphocyte activation and migration, validated against B16-melanoma in mice experiments.
• UISS-Multiple Sclerosis (UISS-MS) Multi-scale agent-based platform simulating multiple sclerosis immune dynamics and predicting disease progression and treatment response using patient-specific data such as age, sex, MRI lesion load, and therapy history.
• UISS-COVID-19 In silico platform simulating immune system responses against SARS-CoV-2, providing insights into virus dynamics, immune interactions, and therapeutic outcomes to accelerate vaccine development against COVID-19.
• UISS-Flu In silico platform simulating immune responses to influenza A and identifying optimal adjuvants, including citrus-derived Beta Sitosterol, for enhanced vaccine efficacy.
• UISS-Sense In silico platform simulating human immune responses to skin sensitizers to deliver accurate allergenicity prediction and mechanistic immunotoxicity evaluation as an alternative to animal testing.
• UISS-TOX Computational platform assessing immunotoxic effects of chemicals such as PFAS, predicting adverse outcomes including weakened vaccine responses and increased susceptibility to infections or cancer.
• UISS-TB-DR (Tuberculosis Drug-Resistant) Simulation platform for drug-resistant tuberculosis modeling in silico, developed within the In Silico World Consortium and recognized by EMA with a Letter of Support as a regulatory-grade tool for tuberculosis vaccine development.

Quantifiable outcome

• Drug development timeline reduction from preclinical to Phase I trials
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature10 records

Partnerships

Nine partnerships are on record, tiered core, major and supporting.

• In Silico World (ISW) ConsortiumcoreStrategic or Co-development Partner · 6 February 2024Mimesis participated in the In Silico World Consortium, a collaborative initiative that secured world-first preliminary regulatory acceptance from EMA for the UISS-TB-DR simulation platform. The consortium brings together leading organizations advancing in silico medicine.
• Avicenna AlliancecoreStrategic or Co-development Partner · 10 March 2023Mimesis became a member of the Avicenna Alliance for Predictive Medicine, joining regulators, scientists, researchers, and industry leaders to advance in silico methods. Professor Pappalardo serves on the Board of Directors of the Avicenna Alliance.
• University of CataniacoreStrategic or Co-development PartnerMimesis is a spin-off of the University of Catania. Key team members including Professor Francesco Pappalardo (Deputy Director, Department of Pharmaceutical and Health Sciences) and Dr. Giulia Russo hold academic positions at the university.
• COmbine GroupmajorStrategic or Co-development PartnerMimesis presented alongside the COmbine Group at the VPH2024 conference in Stuttgart, showcasing collaborative contributions to the In Silico World project.
• Istituto Europeo di OncologiamajorStrategic or Co-development PartnerCollaboration using anonymized patient data from Istituto Europeo di Oncologia for expanding UISS-Mammary Carcinoma to clinical applications and validating predictive accuracy.
• VPH InstitutemajorStrategic or Co-development PartnerProfessor Pappalardo founded and directed the VPH Institute for Integrative Biomedical Research, representing Mimesis's strong connection to this key integrative biomedical research organization.
• ICSC (Italian Center for Supercomputing)supportingTechnology or IntegrationProfessor Francesco Pappalardo serves as co-leader of Spoke 8 'In Silico Medicine and Omics Data' at ICSC, utilizing supercomputing resources for computational medicine research.
• Observatory on Trends and Applications of SupercomputingsupportingTechnology or IntegrationMimesis participated in events organized by the Observatory to explore supercomputing potential for healthcare and computational medicine applications.
• European Medicines Agency (EMA)coreStrategic or Co-development PartnerEMA provided preliminary regulatory acceptance and Letter of Support for the UISS-TB-DR platform, marking a historic milestone for in silico medicine regulatory pathways.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Schrödinger: Schrödinger provides a physics-based computational platform for drug discovery and materials science, including predictive modeling of molecular and biological properties. It is a broader incumbent whose platform competes for the same pharma R&D budget pool.
• Evidera: Evidera (part of PPD/Thermo Fisher) provides real-world evidence, health economics, and modeling services to support pharma development and market access. It is a broader incumbent offering complementary modeling services to pharma clients.

Direct peers

• Certara: Certara is a leading biosimulation software and services company for drug development, offering model-informed drug development, PBPK, and regulatory science solutions. It is the most direct commercial peer to Mimesis's in silico trial and immunomodulation modeling work.
• Simulations Plus: Simulations Plus provides modeling and simulation software (GastroPlus, MonolixSuite, Immunetrics) used in drug development and immunogenicity assessment. Its Immunetrics platform overlaps directly with Mimesis's immune system simulation focus.
• CytoReason: CytoReason builds cell-based computational models of the human immune system for pharma R&D, particularly in autoimmune and inflammatory disease. It is a closely comparable peer focused on immune system modeling for drug development.
• GNS Healthcare: GNS Healthcare applies causal AI and simulation to patient-level data to support pharma drug development and precision medicine. It shares Mimesis's positioning around computational models informing therapy selection and development.
• Lhasa Limited: Lhasa Limited develops in silico and knowledge-based solutions for chemical safety, including immunotoxicity and skin sensitization prediction. Its work closely mirrors Mimesis's UISS-Sense and UISS-TOX product areas.
• InSilicoTrials Technologies: InSilicoTrials operates a cloud platform for in silico trials spanning multiple therapeutic areas and engineering disciplines, sharing Mimesis's core proposition of using computational simulation to reduce animal and human testing in regulatory submissions.
• Insilico Medicine: Insilico Medicine is an AI-driven drug discovery company that combines generative AI with biological modeling to advance pipelines across oncology, fibrosis, and immunology. It competes for the same in silico drug development budgets as Mimesis.

Others

• Insigneo Institute: Insigneo Institute is a University of Sheffield-led research consortium for in silico medicine founded and previously directed by Mimesis co-founder Professor Pappalardo. It is a closely linked ecosystem participant rather than a commercial competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/MimesisSrl
• YouTubeyoutube.com/channel/UCTb_s6EHv77VYqFtnXc8p0A
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/mimesis-srl
• Instagraminstagram.com/mimesis.srl

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mimesis